Service de génétique médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France.
Centre de Référence du syndrome de Marfan et des syndromes apparentés, Hôpital des Enfants, CHU de Toulouse, Toulouse, France.
Mol Genet Genomic Med. 2020 May;8(5):e1132. doi: 10.1002/mgg3.1132. Epub 2020 Mar 10.
Pathogenic SMAD3 variants are responsible for a cardiovascular phenotype, mainly thoracic aortic aneurysms and dissections. Precocious identification of the vascular risk such as aortic dilatation in mutated patients has a major impact in terms of management, particularly to avoid dissection and sudden death. These vascular damages are classically associated with premature osteoarthritis and skeletal abnormalities. However, variable expressivity and incomplete penetrance are common with SMAD3 variants.
To investigate the clinical variability observed within SMAD3 patients, we reviewed the phenotypic and genetic data of 22 new patients from our Centre and of 133 patients reported in the literature. From this cohort of 155 mutated individuals, we first aimed to delineate an estimated frequency of the main clinical signs associated with SMAD3 pathogenic variants and, then, to look for genotype-phenotype correlations, mainly to see if the aortic phenotype (AP) could be predicted by the SMAD3 variant type.
We showed, herein, the absence of correlation between the SMAD3 variant type and the occurrence of an AP in patients.
Therefore, this report brings additional data for the genotype-phenotype correlations of SMAD3 variants and the need to explore in more detail the effects of genetic modifiers that could influence the phenotype.
致病性 SMAD3 变异可导致心血管表型,主要为胸主动脉瘤和夹层。在突变患者中及早识别血管风险(如主动脉扩张)对管理具有重大影响,特别是可避免夹层和猝死。这些血管损伤通常与早发性骨关节炎和骨骼异常有关。然而,SMAD3 变异存在表现度可变和不完全外显率的情况。
为了研究 SMAD3 患者中观察到的临床变异性,我们回顾了我们中心 22 名新患者和文献中报道的 133 名患者的表型和遗传数据。从这 155 名突变个体的队列中,我们首先旨在描绘与 SMAD3 致病性变异相关的主要临床体征的估计频率,然后寻找基因型-表型相关性,主要是观察是否可以通过 SMAD3 变异类型来预测主动脉表型(AP)。
我们在此表明,SMAD3 变异类型与患者中 AP 的发生之间不存在相关性。
因此,本报告为 SMAD3 变异的基因型-表型相关性提供了额外的数据,并需要更详细地探讨可能影响表型的遗传修饰因子的作用。